News

Submitted proposals - HORIZON-CL5-2023-D6-01 (closed on 05/09/2023)

Published on | 1 year ago

Programmes Climate, Energy, Mobility

For the above mentioned call a total of 133 proposals were submitted. 

The breakdown per topic is:

HORIZON-CL5-2023-D6-01-01 (RIA): 16 proposals

HORIZON-CL5-2023-D6-01-02 (RIA): 3 proposals

HORIZON-CL5-2023-D6-01-03 (IA): 10 proposals

HORIZON-CL5-2023-D6-01-04 (RIA): 7 proposals

HORIZON-CL5-2023-D6-01-05 (RIA): 6 proposal

HORIZON-CL5-2023-D6-01-06 (RIA): 29 proposal

HORIZON-CL5-2023-D6-01-07 (RIA): 13 proposals

HORIZON-CL5-2023-D6-01-08 (CSA): 3 proposals

HORIZON-CL5-2023-D6-01-09 (IA): 7 proposals

HORIZON-CL5-2023-D6-01-10 (RIA): 21 proposals

HORIZON-CL5-2023-D6-01-11 (RIA): 11 proposals

HORIZON-CL5-2023-D6-01-12 (RIA): 6 proposals

HORIZON-CL5-2023-D6-01-13 (CSA): 1 proposal

Source: Funding and Tender Portal

myOverview - sign up for personalised information

We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).

Stay informed about what matters to you. By signing up, you can opt in for e-mail notifications and get access to a personalised dashboard that groups all news updates and event announcements in your domain(s).

Only for stakeholders located in Flanders

Latest News

1601 articles available search in articles 

Testimonial

image of Methylomic – Hope & Improved outcomes for Crohn’s disease patients across Europe

Methylomic – Hope & Improved outcomes for Crohn’s disease patients across Europe

The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.